Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.
Zuily S, Cohen H, Isenberg D, Woller SC, Crowther M, Dufrost V, Wahl D, Doré CJ, Cuker A, Carrier M, Pengo V, Devreese KMJ. Zuily S, et al. Among authors: dore cj. J Thromb Haemost. 2020 Sep;18(9):2126-2137. doi: 10.1111/jth.14935. J Thromb Haemost. 2020. PMID: 32881337 Free article.
Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.
Cohen H, Doré CJ, Clawson S, Hunt BJ, Isenberg D, Khamashta M, Muirhead N; RAPS Trial Protocol Collaborators. Cohen H, et al. Among authors: dore cj. Lupus. 2015 Sep;24(10):1087-94. doi: 10.1177/0961203315581207. Epub 2015 May 4. Lupus. 2015. PMID: 25940537 Free PMC article. Clinical Trial.
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.
Cohen H, Hunt BJ, Efthymiou M, Arachchillage DR, Mackie IJ, Clawson S, Sylvestre Y, Machin SJ, Bertolaccini ML, Ruiz-Castellano M, Muirhead N, Doré CJ, Khamashta M, Isenberg DA; RAPS trial investigators. Cohen H, et al. Among authors: dore cj. Lancet Haematol. 2016 Sep;3(9):e426-36. doi: 10.1016/S2352-3026(16)30079-5. Lancet Haematol. 2016. PMID: 27570089 Free PMC article. Clinical Trial.
Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial.
Jones A, Muller P, Dore CJ, Ikeji F, Caverly E, Chowdhury K, Isenberg DA, Gordon C, Ehrenstein MR. Jones A, et al. Among authors: dore cj. BMJ Open. 2019 Dec 16;9(12):e032569. doi: 10.1136/bmjopen-2019-032569. BMJ Open. 2019. PMID: 31848169 Free PMC article. Clinical Trial.
Optimal timing of anticoagulation after acute ischemic stroke with atrial fibrillation (OPTIMAS): Protocol for a randomized controlled trial.
Best JG, Arram L, Ahmed N, Balogun M, Bennett K, Bordea E, Campos MG, Caverly E, Chau M, Cohen H, Dehbi HM, Doré CJ, Engelter ST, Fenner R, Freemantle N, Hunter R, James M, Lip GY, Murray ML, Norrving B, Sprigg N, Veltkamp R, Zaczyk I, Werring DJ; OPTIMAS investigators. Best JG, et al. Among authors: dore cj. Int J Stroke. 2022 Jun;17(5):583-589. doi: 10.1177/17474930211057722. Epub 2022 Jan 12. Int J Stroke. 2022. PMID: 35018878
Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids.
Ibrahim F, Choy E, Gordon P, Doré CJ, Hakim A, Kitas G, Isenberg D, Griffiths B, Lecky B, Chakravarty K, Winer J, Danko K, Cooper RG, White-Alao B, Scott DL. Ibrahim F, et al. Among authors: dore cj. Rheumatology (Oxford). 2015 Jun;54(6):1050-5. doi: 10.1093/rheumatology/keu442. Epub 2014 Nov 27. Rheumatology (Oxford). 2015. PMID: 25433040 Free PMC article. Clinical Trial.
Ophthalmic statistics note 6: effect sizes matter.
Cook JA, Bunce C, Doré CJ, Freemantle N; Ophthalmic Statistics Group. Cook JA, et al. Among authors: dore cj. Br J Ophthalmol. 2015 May;99(5):580-1. doi: 10.1136/bjophthalmol-2014-306303. Epub 2015 Feb 26. Br J Ophthalmol. 2015. PMID: 25722490 Free PMC article. No abstract available.
Ophthalmic statistics note 8: missing data--exploring the unknown.
Bunce C, Quartilho A, Freemantle N, Doré CJ; Ophthalmic Statistics Group. Bunce C, et al. Among authors: dore cj. Br J Ophthalmol. 2016 Mar;100(3):291-4. doi: 10.1136/bjophthalmol-2015-307821. Epub 2015 Dec 30. Br J Ophthalmol. 2016. PMID: 26719490 Free article. No abstract available.
212 results